在AI医疗领域，华大智造"AI+基因测序"布局领先。近年华大智造持续推进实验室智能自动化 (GLI) 业 务升级，通过人工智能技术全面重构其实验室自动化业务，加速 AI 驱动软件工具开发，为智能生态提 供底层支撑。在脑机接口方面，其Stereo-seq时空组学技术，能为植入式脑机接口提供厘米级全景视场 与纳米级分辨率的导航支撑。目前，公司已与上海脑科学与类脑研究中心等顶级机构合作，深度参 与"全脑介观神经联接图谱"大科学计划。 根据Grand View Research报告显示，2024年全球AI医疗市场规模约为266.5亿美元，预计到 2033年将飙 升至约5055.9亿美元，期间年复合增长率达38.8%。叠加1月6日华大智造被正式调入中证A500指数的利 好，公司在AI医疗万亿赛道中，有望凭借全产业链布局持续释放增长潜力。 智通财经APP观察到，AI医疗赛道近期表现强势，OpenAI推出ChatGPT Health功能、蚂蚁阿福月活破 3000万，带动板块全线走强。作为生命科学上游龙头，华大智造(688114.SH)集智能医疗、机器人、脑 机接口、合成生物等多重热点于一身，成为资本市场高度关注的核心标的。 ...

东莞证券表示，随着国内科技巨头积极布局AI医疗赛道，有望快速推进我国医疗信息化和普惠化进 程，并加速AI垂类应用场景落地，医疗或成为AI垂类应用场景的重要突破口。 责任编辑：栎树 据媒体报道，OpenAI宣布推出ChatGPT Health（健康），该模式集成于ChatGPT中，是一个"专门用于 与ChatGPT进行健康相关对话的独立空间"，可以连接电子医疗记录和各类健康应用，生成的回复能够 结合用户的健康信息与个人情境。 股票频道更多独家策划、专家专栏，免费查阅>> 全球AI医疗市场正迈入万亿级增长通道。据Grand View Research报告显示，2024年全球AI医疗市场规模 约为266.5亿美元（约合人民币1861亿元），预计到2033年将飙升至约5055.9亿美元（约合人民币3.5万 亿元），期间年复合增长率达38.8%。 ...

Group 1 - OpenAI launched "ChatGPT Health," a dedicated space for health-related conversations integrated within ChatGPT, which connects to electronic medical records and various health applications [1] - The product promises that health conversation data will not be used for model training and employs specialized encryption and isolation technologies to address medical data privacy concerns [1] - The initiative aims to integrate fragmented health data, providing personalized services such as interpretation of test results and diet/exercise planning, positioning itself as a smart assistant throughout the health management lifecycle [1] Group 2 - In China, AI medical support policies are set to be introduced intensively by 2025, with a clear path outlined for AI applications in clinical diagnosis, patient services, and traditional Chinese medicine by 2030 [2] - The Ant Group's "Afu" app has seen its monthly active users double to 30 million after a brand upgrade, with daily inquiries exceeding 10 million, indicating strong market acceptance for applications that integrate health consultation with full-service capabilities [2] - The global AI medical market is projected to reach approximately $26.65 billion in 2024, with expectations to soar to about $505.59 billion by 2033, reflecting a compound annual growth rate of 38.8% [2]

影响股市利好与利空消息 宏观新闻 1、国务院总理李强1月9日主持召开国务院常务会议，部署实施财政金融协同促内需一揽子政策，研究 推行常住地提供基本公共服务有关工作，审议通过《中华人民共和国自然保护区条例（修订草案）》。 会议指出，要加强财政政策与金融政策配合联动，充分发挥政策效应，引导社会资本参与促消费、扩投 资。会议还指出，完善随迁子女教育政策，扩大公租房保障范围。 2、证监会副主席陈华平1月11日表示，将持续完善长钱长投的制度环境，合力推动各类中长期资金进一 步提高入市规模比例；将进一步提升监管执法有效性，持续健全投资者教育服务和保护体系，坚持依法 从严监管，突出打大、打恶、打重点，从严惩治各类恶性违法行为。 3、证监会公布《证券期货违法行为"吹哨人"奖励工作规定》，自公布之日起施行。《规定》较大幅度 提高奖励标准，提高奖金比例，最高奖励100万元。 4、全国商务工作会议1月10日至11日在京召开，会议指出，2026年全国商务系统要重点做好八个方面工 作，包括加快培育服务消费新增长点，优化消费品以旧换新政策实施等。 5、为规范互联网应用程序个人信息收集使用活动，保护个人信息权益，促进个人信息合理利用，国家 ...

宏 观 新 闻 1、国务院总理李强1月9日主持召开国务院常务会议，部署实施财政金融协同促内需一揽子政策，研究推行常住地提供基本公共服务 有关工作，审议通过《中华人民共和国自然保护区条例（修订草案）》。会议指出，要加强财政政策与金融政策配合联动，充分发挥 政策效应，引导社会资本参与促消费、扩投资。会议还指出，完善随迁子女教育政策，扩大公租房保障范围。 早 报 精 选 1、国常会：部署实施财政金融协同促内需一揽子政策。 2、两部门：4月起，取消光伏等产品增值税出口退税。 3、证监会：推动各类中长期资金进一步提高入市规模比例。 4、我国2025年12月向ITU申请了超20万颗卫星的频轨资源。 5、证监会对天普股份股票交易异常波动公告涉嫌重大遗漏立案调查。 2、证监会副主席陈华平1月11日表示，将持续完善长钱长投的制度环境，合力推动各类中长期资金进一步提高入市规模比例；将进 一步提升监管执法有效性，持续健全投资者教育服务和保护体系，坚持依法从严监管，突出打大、打恶、打重点，从严惩治各类恶性 违法行为。 3、证监会公布《证券期货违法行为"吹哨人"奖励工作规定》，自公布之日起施行。《规定》较大幅度提高奖励标准，提高奖金比 ...

"最后一公里"畅通与否，关乎人工智能技术能否在基层落地生根，最终能否让优质医疗资源突破时空壁 垒，切实缓解"看病难、看病贵"的民生关切。当前，加速构建的紧密型县域医共体智慧云平台，正是打 通这一堵点的核心枢纽。这条以省县联动、多级协同为支撑的智慧"高速路"，高效贯通上级医院的专 家、技术与数据资源，助力AI影像诊断、远程会诊等智能服务精准下沉基层，使优质医疗服务便捷可 及、"家门口"可享，显著提升了健康服务的公平性与可及性。 【专家点评】 作者：梅浩（工业和信息化部网络空间公共安全研究中心特约研究员） 以大模型为代表的新一代人工智能技术，深度赋能医疗健康领域，在医学影像判读、疾病风险预警、辅 助诊疗决策等领域展现出巨大潜力和应用价值，有力助推临床诊疗模式优化升级，为解决医疗资源分布 不均难题、推动优质医疗资源扩容下沉注入新动能。深化人工智能在医疗健康领域的融合应用，打通 AI医疗落地应用的"最后一公里"，是让技术创新红利真正惠及亿万民众健康福祉的关键所在。 推动AI深度融入临床实践与基层健康服务体系。坚决摒弃"技术空转"，牢固树立以临床需求为导向的研 发应用理念。聚焦"最后一公里"攻坚，将AI技术部署深度嵌入 ...

截至2026年1月9日收盘，美年健康(002044)报收于6.13元，上涨10.05%，涨停，换手率4.37%，成交量 169.29万手，成交额10.25亿元。 当日关注点 交易信息汇总资金流向 1月9日主力资金净流入4.22亿元；游资资金净流出1.86亿元；散户资金净流出2.36亿元。 大宗交易 1月9日美年健康现202.29万元大宗交易。 董秘最新回复 投资者： 董秘您好！想请教下公司与蚂蚁阿福有什么合作吗，谢谢！ 董秘： 尊敬的投资者，您好！感谢您对公司业务发展的关心！敬请关注公司公告。谢谢！ 投资者： 尊敬的董秘您好！请问公司目前是否与蚂蚁阿福（原 AQ 平台）存在业务合作，或在健康管 理、AI 医疗等相关领域有接入合作计划？已知蚂蚁阿福聚焦医疗健康服务生态建设， 战略并与多家科 技企业合作，想请问公司与蚂蚁阿福是否存在产品接入、技术协同等方面的合作？ 来自交易信息汇总：1月9日主力资金净流入4.22亿元，显示主力对美年健康股票的积极介入。 来自交易信息汇总：当日发生202.29万元大宗交易，反映特定投资者之间的较大规模股份转让。 ...

Investment Rating - The report maintains a "Positive" investment rating for the pharmaceutical industry [4] Core Insights - The pharmaceutical index rose by 7.81% from January 5 to January 9, outperforming the CSI 300 index by 5.03%. The brain-machine interface and AI medical sectors are expected to remain active in Q1 2026, with a strong rebound in innovative drugs, particularly small nucleic acids [5][25] - The report highlights the potential for significant advancements in small nucleic acids in 2026, driven by breakthroughs in liver-targeted delivery technologies and a surge in clinical data readouts [8][22] - The report emphasizes the importance of selecting innovative drug stocks with strong fundamentals and suggests focusing on companies that have undergone sufficient adjustments [5][49] Summary by Sections Industry Performance - The pharmaceutical index saw 443 stocks rise and 25 fall during the week, with notable gainers including Innovative Medical (+61.04%) and Sanbo Brain Science (+56.15%). Conversely, Baohua Pharmaceutical saw a decline of -21.65% [5][26][27] Small Nucleic Acids - 2026 is projected to be a pivotal year for the small nucleic acid sector, with advancements in liver-targeted delivery technologies and a high frequency of clinical data readouts expected [8][22] - Arrowhead's delivery platform has shown promising results in clinical trials, validating the feasibility of RNAi therapies for obesity and other conditions [9][11] Investment Recommendations - The report suggests focusing on companies with leading platform capabilities and differentiated pipeline layouts, such as Rebio Biotech, Yuyuan Pharmaceutical, and Frontier Biotech [20][24] - It also recommends a diversified investment approach, including innovative drugs, brain-machine interfaces, and AI medical technologies [47][48] Market Trends - The report notes that the aging population and increasing healthcare demands are driving growth in the pharmaceutical sector, with a focus on chronic diseases and innovative medical technologies [47] - The report highlights the ongoing trend of domestic companies enhancing their capabilities in the global market, particularly in innovative drug development and medical devices [46][47] Key Companies to Watch - Recommended stocks include China National Pharmaceutical Group, Rebio Biotech, Shanghai Yizhong, and Yuyuan Medical [49]

丨证券研究报告丨 [Table_Author] 行业研究丨点评报告丨软件与服务 [Table_Title] AI 产业跟踪：OpenAI 正式推出 ChatGPT Health，关注 AI 医疗板块机遇与价值重估 报告要点 宗建树 刘思缘 SAC：S0490520030004 SFC：BUX668 请阅读最后评级说明和重要声明 [Table_Summary] 1 月 7 日，OpenAI 推出 ChatGPT Health，定位专为健康和保健设计的 ChatGPT 专属体验。 当前下沉市场的巨大医疗需求得到验证，Agent 接管个人健康的时代正在开启。近期海内外 AI 医疗积极变化频出，海外大厂积极布局医疗领域+国内中试基地陆续取得里程碑成果，我们看好 AI 在医疗领域渗透率持续提升的前景，建议关注从具备优质数据的垂类玩家和超级流量入口大 厂，及其 AI 结合专业数据赋能医药、医疗的商业化场景落地进展。 分析师及联系人 %% %% %% %% research.95579.com 1 软件与服务 cjzqdt11111 [Table_Title AI 产业跟踪：2] OpenAI 正式推出 ChatGPT H ...

Group 1 - The report highlights the launch of "ChatGPT Health" by OpenAI, which integrates health-related conversations and connects to electronic medical records, indicating a significant potential market for AI in healthcare [9][12] - The "Artificial Intelligence + Manufacturing" initiative aims to achieve reliable supply of core AI technologies and maintain a leading position in the industry by 2027, with specific targets including the application of 3-5 general large models in manufacturing and the creation of 100 high-quality industrial datasets [12][14] - The report identifies key sectors such as AI healthcare, AI pharmaceuticals, and AI biomanufacturing as focal points for development, proposing measures like building intelligent drug discovery platforms and smart supply chain management systems [16][12] Group 2 - The North Exchange's biopharmaceutical sector saw a weekly increase of 5.85%, with medical devices rising by 7.81%, indicating strong market performance [23][26] - Among the biopharmaceutical companies, 90.48% experienced stock price increases, with notable performers including BeiYikang (+45.1%) and XinGanjian (+10.46%) [33][34] - As of January 9, 2026, there are 15 companies in the biopharmaceutical sector awaiting approval on the North Exchange, with an average projected revenue of 424 million yuan for 2024 [34][38] Group 3 - The report emphasizes the importance of AI in enhancing drug development efficiency and supply chain management, aiming to reduce costs and time in pharmaceutical processes [16][12] - The global AI healthcare market is projected to reach approximately $26.65 billion in 2024, with a compound annual growth rate (CAGR) of 38.8% expected until 2033 [18][17] - The Chinese AI healthcare industry is expected to grow from 97.3 billion yuan in 2023 to 159.8 billion yuan by 2028, reflecting significant growth potential in this sector [18][19]